Lilly's oral GLP-1 orforglipron consistent with injectable GLP-1 medicines owenhaskins Apr 17, 2025 3 min read The topline Phase 3 results from Eli Lilly ACHIEVE-1 study, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone, have revealed that orforglipron met the primary endpoint of superior A1C reduction compared to placebo at 40 weeks
To date, incretin-based approaches for obesity management appear as the most promising and rapidly developing (Supplementary Table 1), with innovations such as once-weekly (OW) injectable triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), cagrilintide (long-acting amylin analogue)/semaglutide 2.4 mg (CagriSema) combination, GCGR/GLP-1R dual agonists, high-dose oral semaglutide, and oral non-peptide GLP-1 receptor agonist orforglipron, with relevant implications in terms of patients compliance and environmental sustainability
No se recomienda la restriccin de colina en embarazadas ni en nios en edad de crecimiento
N de lot / A consommer de prfrence avant : voir le n de lot et la date indiqus sur le flacon
In the tirzepatide OSA trial, patients saw significant drops in AHI and body weight along with reductions in systolic pressure and inflammation markers
